Pfizer and valneva initiate phase 3 study of lyme disease vaccine candidate vla15

New york & saint-herblain, france--(business wire)--pfizer inc. (nyse: pfe) and valneva se (nasdaq: valn; euronext paris: vla) today announced the initiation of a phase 3 clinical study, vaccine against lyme for outdoor recreationists (valor) (nct05477524), to investigate the efficacy, safety and immunogenicity of their investigational lyme disease vaccine candidate, vla15. “with increasing global rates of lyme disease, providing a new option for people to help protect themselves from the disea
VALN Ratings Summary
VALN Quant Ranking